IF metformin (500 mg/kg/day in drinking water, oral administration — a dose translating from established murine pharmacokinetics) is administered to aged (20–24-month-old) C57BL/6J female mice with established RPE lysosomal A2E and lipofuscin accumulation,

THEN a measurable degradation of pre-existing A2E deposits within RPE cells — quantified as ≥30% reduction in fundus autofluorescence (488 nm excitation, confocal scanning laser ophthalmoscopy) and a corresponding reduction in biochemically extracted A2E (HPLC-MS from RPE flatmounts) — will be observed alongside restoration of lysosomal acidification (LysoSensor DND-189 ratiometric assay, pH recovery toward 4.5–5.0) and transcriptional upregulation of the CLEAR network (LAMP1, CTSD, ATP6V0C; RT-qPCR and Western blot from RPE isolates) within 12 weeks of treatment,

BECAUSE the following step-by-step causal chain operates to REPAIR, not merely prevent, accumulated LysoSENS damage:

1. In aged RPE, mitochondrial dysfunction drives elevated reactive oxygen species, which aberrantly hyperactivate mTORC1 and p70S6K — a conserved senescent signaling state — (aberrant mTOR activation in senescent and aged tissues is mechanistically linked to mitochondrial ROS)[https://doi.org/10.1016/j.exger.2014.11.004], causing sustained phosphorylation of TFEB at Ser142 and Ser211 and cytoplasmic sequestration by 14-3-3 proteins.
2. Simultaneously, A2E that has accumulated in lysosomes inhibits the vacuolar H⁺-ATPase (v-ATPase) proton pump, raising intralysosomal pH above 5.0, directly impairing Cathepsin D and acid phosphatase activity and blocking autophagic flux — and because mTORC1 lysosomal surface recruitment itself depends on v-ATPase activity as a pH-sensing scaffold, this A2E-driven alkalinization further sustains pathological mTORC1 hyperactivation, creating a self-reinforcing damage loop [SPECULATIVE — mechanistic link between A2E-mediated v-ATPase inhibition and secondary mTORC1 overactivation at the lysosomal surface has not been directly demonstrated in RPE; inferred from canonical mTORC1 lysosomal sensing literature and the functional rescue findings in RPE] (lysosomal compromise blocks POS degradation and increases lipofuscin-like autofluorescence, and rescue of lysosomal acidification reverses this)[https://doi.org/10.1007/978-1-4614-3209-8_14].
3. Metformin inhibits mitochondrial Complex I, raising the intracellular AMP/ATP ratio and activating AMPK — this is mechanistically distinct from rapamycin's allosteric mTORC1 inhibition, which entirely depends on the mTOR surface complex and cannot bypass A2E-driven v-ATPase dysfunction.
4. AMPK directly phosphorylates TFEB at Ser467 (human) / Ser555 (murine) — a phosphorylation site that promotes nuclear import independently of mTORC1 phosphorylation status — thereby enabling TFEB nuclear translocation even in the context of persistent A2E-mediated v-ATPase inhibition and residual mTORC1 activity (AMPK-dependent TFEB activation operates through dire...

SENS category: RepleniSENS

Key references: • doi.org/10.1016/j.exger.2014.11.004], • doi.org/10.1007/978-1-4614-3209-8_14]. • doi.org/10.1523/jneurosci.0705-15.2015]. • doi.org/10.3390/ijms19051416]. • doi.org/10.1016/j.fob.2014.11.003],